Last updated: February 21, 2026
What Is NDC 62011-0019?
NDC 62011-0019 is the National Drug Code for [Identify the drug]. This drug is used primarily for [indication] and is marketed by [manufacturer]. It has been approved since [approval date] and is available in [dosage form and strength].
Market Size and Competitors
Primary Indications
- [Indication 1]: Estimated market size of [revenue, volume].
- [Indication 2]: Estimated market size of [revenue, volume].
Competitors
- [Competitor 1]: Market share [percentage], price range [range].
- [Competitor 2]: Market share [percentage], price range [range].
- [Other competitors].
Market Trends
- Growing demand driven by [e.g., increasing prevalence, new indications].
- Entry of biosimilars or generics expected within [timeframe], potentially reducing prices.
Pricing Strategy and Current Price
Current Price Range
- Wholesale acquisition cost (WAC): approximately $X per [unit].
- Average retail price: approximately $Y per [unit].
- Price differences across regions or payers.
Influencing Factors
- Patent status: Patent expiration in [year] may trigger price reductions.
- Reimbursement policies influencing net prices.
- Manufacturer discounts, rebates, and contracting practices.
Comparison with Similar Drugs
| Drug Name |
Indication |
Price Range (WAC) |
Market Share |
| [Drug A] |
[indication] |
$X – $Y |
[percentage] |
| [Drug B] |
[indication] |
$Z – $W |
[percentage] |
Price Projections
Short-term (1-2 years)
- Price stability expected unless patent expiry occurs.
- Anticipated slight upward adjustments due to inflation or supply chain costs.
- Impact of formulary negotiations and payer policies.
Medium-term (3-5 years)
- Price reduction likely if biosimilars or generics enter the market.
- Patent expiry forecasted for [year].
- If patents are maintained, prices could either stay stable or increase marginally within a 2-5% range annually.
Long-term (5+ years)
- Possible significant price decrease post-patent expiration.
- Entry of biosimilars or alternative therapies could further reduce prices.
- Market penetration of innovative or biosimilar options could shift demand dynamics.
Policy and Regulatory Impact
- [FDA] approvals will influence market size and pricing.
- CMS and private payer policies on drug coverage will affect affordability and market penetration.
- International pricing initiatives may influence U.S. prices, especially in jurisdictions adopting reference pricing.
Investment and R&D Outlook
- Continued R&D efforts by manufacturer for new indications or formulations.
- License agreements or partnerships affecting market access.
- Potential pipeline drugs or biosimilars entering the market over the next 5 years.
Key Factors Impacting Price Trajectory
- Patent status and exclusivity period.
- Entry of biosimilars or generics.
- Payer reimbursement pressures.
- Regulatory approvals for additional indications.
- Supply chain stability and manufacturing costs.
Key Takeaways
- Current price range: approximately $X – $Y per [unit].
- Patent expiry is projected for [year], likely leading to price reductions.
- Market size depends heavily on [indication] prevalence and competitive landscape.
- Generic and biosimilar competition anticipated to lower prices over 3-5 years.
- Policy shifts and payer strategies will significantly influence future prices.
Frequently Asked Questions
1. When is patent expiration for NDC 62011-0019?
Projected patent expiration is [year] based on current patent filings and extensions.
2. What are the main competitors for this drug?
Competitors include [name 1] and [name 2], which offer similar indications with slightly different efficacy profiles and pricing.
3. How might biosimilar entry affect prices?
Biosimilars are expected to reduce prices by [percentage], especially post-patent expiry, due to increased competition.
4. What factors influence the drug’s current pricing?
Patent status, reimbursement policies, manufacturer discounts, and market demand.
5. Are there upcoming regulatory approvals that could impact pricing?
Yes, approval for [additional indications or formulations] could increase market size and influence pricing.
References
- [1] U.S. Food and Drug Administration. (2022). Approved drug products.
- [2] IQVIA. (2023). National prescription drug data.
- [3] CMS. (2022). Medicare Part D drug pricing reports.
- [4] FDA. (2021). Biosimilar guidance documents.
- [5] MarketWatch. (2022). Pharma industry analysis.
Note: Specific drug identification, manufacturer, and indication details require further clarification.
